Clinical trial
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic…
NCT00389285 · ZymoGenetics, Industry · Completed
Key facts
| NCT number | NCT00389285 |
|---|---|
| Title | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma |
| Official title | A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered Concomitantly With Sorafenib (Nexavar) in Subjects With Metastatic Renal Cell Carcinoma |
| Lead sponsor | ZymoGenetics, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Renal Cell |
| Intervention type | Drug |
| Interventions | rIL-21 only, rIL-21 + sorafenib |
| Enrollment | 52 |
| Start date | Oct 1, 2006 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Oct 18, 2006 |
| Last update posted | May 27, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: